1
- --------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE
ACT OF 1934
Date of Report (Date of earliest event reported)
March 30, 1999 (March 26, 1999)
ABGENIX, INC.
-------------
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation or organization)
000-24207 94-3248826
--------- ----------
Commission File Number (I.R.S. Employer Identification Number)
7601 Dumbarton Circle
Fremont, California 94555
-------------------------
(Address of principal executive offices)
(510) 608-6500
--------------
(Registrant's telephone number, including area code)
2
ABGENIX, INC.
FORM 8-K
MARCH 30, 1999
Item 5. Other Events
On March 26, 1999, Abgenix announced that it signed a research
collaboration agreement with BASF Bioresearch Corporation. The press release has
been filed as an exhibit to this Report on Form 8-K.
3
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunder duly authorized.
ABGENIX, INC.
Date: March 30, 1999
/s/ R. SCOTT GREER
-------------------------------------
R. Scott Greer
President and Chief Executive Officer
4
Item 7. Financial Statements and Exhibits
(c) Exhibits (in accordance with Item 601 of Regulation S-K)
99.1 Press Release of Abgenix regarding the signing of a research
collaboration agreement with BASF Bioresearch Corporation.
5
ABGENIX, INC.
Report on Form 8-K
dated March 30, 1999
INDEX TO EXHIBITS
EXHIBIT
NUMBER EXHIBIT NAME
- ------------- -------------------------------------------------------------
99.1 Press Release of Abgenix regarding the signing of a research
collaboration agreement with BASF Bioresearch Corporation.